Pembrolizumab May Effectively Treat Mediastinal B Cell Lymphoma

Share this content:
Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell lymphoma, which usually carries a poor prognosis.
Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell lymphoma, which usually carries a poor prognosis.

Primary mediastinal B cell lymphoma (PMBCL) — a rare subtype of diffuse large B cell lymphoma — is very difficult to treat in the relapsed/refractory setting. A recent study showed, however, that pembrolizumab provides an objective response rate of 41%.1

PMBCL frequently exhibits an abnormality in chromosome 9, which is associated with copy number alterations and rearrangements of the PD-L1 and PD-L2 genes, leading to an overexpression of PD-L1 and PD-L2.

The efficacy and safety of pembrolizumab, a PD-1 inhibitor, were reported from an analysis of 18 patients enrolled in KEYNOTE 013 (ClinicalTrials.gov Identifier: NCT01953692), an ongoing phase 1 study for patients with hematologic malignancies.

The report indicated also that 61% of patients experienced drug-related adverse events, though these events were mostly grade 1 to 2 and generally manageable.

“These positive and interesting results show that pembrolizumab provides outcomes better than salvage therapy in patients with rrPMBCL [relapsed/refractory PMBCL],” Nadia Khan, MD, of the Fox Chase Cancer Center in Philadelphia, Pennsylvania, told Cancer Therapy Advisor.

Dr Khan explained that although 80% to 90% of patients in this setting are cured using first-line therapy with DA EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and DA-EPOCH with rituximab, it is much harder to eradicate disease in relapsed patients. “There are no proven best salvage therapies for these patients,” she said.

KEYNOTE 013 Results

Eleven patients with rrPMBCL received pembrolizumab 10 mg/kg every 2 weeks intravenously for the trial's duration and, after a protocol amendment, 8 patients received a fixed dose of 200 mg every 3 weeks. Treatment continued up to 2 years, until unacceptable toxicity, or until confirmed disease progression. The median duration of follow up was 11.3 months.

Although 19 patients with rrPMBCL were enrolled in the study, by analysis cutoff date, 18 received 1 or more dose of the drug and 1 patient had not yet reached the first response assessment.

RELATED: Cranberry Extract May Help Treat Cancer According to Preclinical Data

In this heavily pretreated group of patients, pembrolizumab was the median fourth line of therapy.

In a safety analysis — a co-primary endpoint — the most common drug-related adverse events were hypothyroidism, diarrhea, nausea, fatigue, pyrexia, and decrease appetite (2 patients each). Grade 3 neutropenia was reported in 1 patient.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters